Clinical Trials Browser

Phase 1/2 × Lymphoma, T-Cell, Peripheral × Lenalidomide × Clear all

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT05105412 2024-07-08

Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas

Phase 1/2 Terminated

12 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT01075321 2020-10-22

Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Phase 1/2 Completed

58 enrolled 12 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

Clinical Trials

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas

Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma